BusinessPROCESSA PHARMACEUTICALS ANNOUNCES THAT IT HAS BEEN ASSIGNED THE LICENSE FOR THE CLINICAL STAGE COMPOUND CTP-499 AND PLANS TO DEVELOP THE DRUG IN MULTIPLE UNMET MEDICAL NEED CONDITIONSBy Nasdaq OMXMar 21, 2018, 1:01 PM UTC
BusinessCleartronic’s (CLRI) ReadyOp™ Software Platform Used in Clinical TrialBy Nasdaq OMXSep 18, 2017, 5:00 PM UTC
BusinessElite Pharmaceuticals’ SequestOx™ Study Results Expected in JulyBy Nasdaq OMXMay 25, 2017, 11:04 AM UTC
BusinessElite Pharmaceuticals’ SequestOx™ Study Results Expected in JulyBy Nasdaq OMXMay 25, 2017, 11:04 AM UTC
BusinessElite Pharmaceuticals’ SequestOx™ Study Results Expected in JulyBy Nasdaq OMXMay 25, 2017, 11:04 AM UTC
BusinessElite Pharmaceuticals’ SequestOx™ Study Results Expected in JulyBy Nasdaq OMXMay 25, 2017, 11:04 AM UTC
BusinessElite Announces U.S. FDA Priority Review Designation for SequestOx™ NDABy Nasdaq OMXMar 17, 2016, 11:00 AM UTC
